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Over the past ten years, studies using the zebrafish model have contributed to our understanding of vertebrate haematopoiesis,
myelopoiesis, and myeloid leukaemogenesis. Novel insights into the conservation of haematopoietic lineages and improvements in
our capacity to identify, isolate, and culture such haematopoietic cells continue to enhance our ability to use this simple organism
to address disease biology. Coupled with the strengths of the zebrafish embryo to dissect developmental myelopoiesis and the
continually expanding repertoire of models of myeloid malignancies, this versatile organism has established its niche as a valuable
tool to address key questions in the field of myelopoiesis and myeloid leukaemogenesis. In this paper, we address the recent
advances and future directions in the field of myelopoiesis and leukaemogenesis using the zebrafish system.
1. Introduction
The zebrafish is emerging as a powerful model system
in which to study haematopoiesis and leukaemogenesis.
In addition to the benefits aﬀorded by scale and sim-
plicity of this versatile genetic model system for studying
developmental aspects of haematopoiesis, the last decade
has seen an explosion of molecular methods and models
to facilitate studies informing on haematopoietic disease
biology, particularly leukaemogenesis and cancer. At its
inception as a cancer model, proliferation and angiogenesis
were proposed as phenotypic attributes as readouts relevant
to cancer pathogenesis [1]. However, it was the generation
of a transgenic zebrafish expressing the C-myc oncogene
under the control of the rag2 promoter that went on to
develop T-cell acute lymphoblastic leukaemia (ALL), which
really revolutionized the view of the scientific world on this
small organism as a cancer disease model [2]. In the ensuing
10 years, many models of oncogene induced cancer have
been generated in zebrafish along withmutagenesis strategies
to identify novel tumour suppressor genes or chromosome
instability loci [3–5]. The utility of such models to answer
key biological questions continues to grow. In this paper, we
focus on developments in the field of myelopoiesis in the
zebrafish, cancer models aﬀecting the myeloid lineages, and
how these have instructed our knowledge on the biology of
these diseases.
2. Zebrafish Myeloid Development
Zebrafish haematopoiesis occurs in two waves in the
developing embryo, termed primitive and definitive [6].
In contrast to human and murine haematopoiesis (where
primitive haematopoiesis initiates with the development of
primitive erythroid cells in the blood islands of the yolk
sac), in zebrafish, primitive wave erythroid cells develop
from caudal lateral plate mesoderm in bilateral stripes that
migrate towards the midline forming a structure termed the
intermediate cell mass (ICM). A population of primitive
macrophages also emerges from a distinct anatomical loca-
tion in the anterior lateral plate mesoderm (ALPM) between
12 and 24 hours after fertilization (hpf) [7, 8]. Definitive
haematopoiesis initiates at around 24 hpf in the posterior
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blood island (PBI), with the emergence of bipotent ery-
thromyeloid progenitors (EMPs). These cells are marked
in their undiﬀerentiated state by combined expression of
gata1 and lmo2 or by expression of cd41 [6]. These cells
have both proliferative and diﬀerentiation potential and
increase in number, peaking at 30–36 hpf. This wave of
haematopoiesis gives rise to further erythrocytes andmyeloid
cells and recently has been shown to give rise to early
mast cells in developing embryos [9]. Multipotent definitive
haematopoietic stem cells (HSCs) expressing cd41, c-myb,
and runx1 arise directly from kdrl-expressing haemogenic
endothelium in the ventral wall of the aorta starting around
26–28 hpf [10, 11]. These cells then migrate to the caudal
haematopoietic tissue (CHT) where they seed and divide
giving rise to all lineages of adult blood cells. These cells
go on to populate the adult organs of haematopoiesis in the
zebrafish, the kidney and the thymus. The precise timing of
the move from primitive wave haematopoiesis to definitive
wave haematopoiesis has yet to be fully established, but
evidence from globin gene expression and mutants with
normal primitive wave blood production suggests that the
major contribution of haematopoiesis comes from definitive
HSC derived cells by around 5 days post fertilization [12–14].
3. Tools for Dissecting Myelopoiesis
Cross-reactive antibodies to zebrafish proteins are lacking,
arguably more so in the haematopoietic system than in
others. This limitation means that the detailed lineage and
diﬀerentiation status analysis of haematopoiesis, so elegantly
understood in the murine system, is currently challenging to
undertake in the zebrafish. Thus a major endeavour in recent
years has been the generation of new tools for such analysis
in the haematopoietic system. Along with the development
of these tools has also come a much broader understanding
of myeloid lineage development in zebrafish. The first
transgenics developed to mark myeloid cells expressed
enhanced green fluorescent protein (eGFP) from the major
myeloid transcription factor pu.1. Tg(spi1/pu.1:eGFP) ani-
mals express eGFP in primitive wave myeloid cells but by 2
days postfertilization (dpf), expression of eGFP in myeloid
cells is markedly reduced as pu.1 expression is downregu-
lated [15, 16]. To visualize neutrophil granulocytes later in
development, several transgenic lines have been generated by
various laboratories. These include the Tg(lysc:dsRed) and
Tg(lysc:eGFP) lines [17] as well as Tg(mpx:eGFP) [18, 19]
and Tg(myd88:eGFP) [20]. While all of these lines label
predominantly neutrophil granulocytes, it is notable that the
overlap in expression of the endogenous transcripts (by in
situ hybridization) or protein (by antibody) as well as the
reporter gene expression between transgenic lines is not fully
concordant, suggesting that subtly diﬀerent populations are
labelled by each transgene depending on the developmental
time point of evaluation [17, 21]. Some of these subtleties
in gene and protein expression have been addressed. L-
plastin specifically has in some early studies been suggested
to mark monocyte/macrophage lineage cells but there is a
clear evidence that this protein is expressed (as in mammals)
in all leucocytes [21]. The Tg(lysc:eGFP) expresses GFP
from 22 hpf, initially in primitive macrophages arising from
the ALPM. Expression of eGFP increases and is notable
in the CHT (likely labelling and diﬀerentiating definitive
myeloid cells) and the developing brain and retina (more
likely to represent the on-going expression in a proportion
of macrophages). To clarify precisely which cells express
the eGFP from the Tg(lysc:eGFP) transgene, Hall et al.
performed anti-GFP staining along with fluorescent in situ
hybridization for mpx, l-plastin, and fms. Dual staining was
observed for eGFP with each of these myeloid transcripts;
however, there were some eGFP (lysc) expressing cells that
did not express mpx, some fms expressing cells that did
not express eGFP (lysc), and some l-plastin expressing
cells that did not express eGFP. Thus, the Tg(lysc:eGFP)
marks primitive macrophages and a majority of developing
granulocytes but does not label all mpx positive granulocytes
or all fms expressing macrophages [17]. It is conceivable that
these subtleties may in time come to give us more detailed
information about subpopulation of myeloid cells, such as
their stage of diﬀerentiation. More recently transgenic lines
using the mpeg1 or fms (csf1r) promoter [22, 23] have been
used to distinguish macrophage populations from granu-
locytic myeloid cells, further enhancing studies of innate
immune system. However, fms reporter animals exhibit
expression in neural crest-derived xanthophores as well as
macrophages, which may result in some limitations in the
use of this system. By contrast, the mpeg1 promoter appears
exclusive to macrophages, but expression in adult fish is
maintained only in zebrafish lines generated using direct
transgenic approaches, and not detectable in those lines in
which mpeg1 is linked to a GAL4/UAS expression system.
To further delineate the expression pattern of macrophages
and other mononuclear phagocytes in adult zebrafish, a
promoter fragment of the MHC class II beta gene, mhc2dab,
was isolated. By virtue of the combined transgene expression,
the Tg(mhc2dab:eGFP) transgenic line in combination with
Tg(CD45:dsRed) (which labels all leukocytes except B cells)
has now allowed identification of macrophages and dendritic
cells as well as B lymphocytes in adult zebrafish tissues [24].
Several recent studies have also delineated additional
granulocytic subpopulations. Zebrafish mast cells can be
identified by expression of the cpa5 transcript, and, like
their mammalian counterpart are positive for toluidine blue,
express mast cell tryptase and Cd117 at the protein level
[25], as well as elements of the Tol-like receptor (TLR)
pathway as evidenced by coexpression of cpa5 and GFP
in the Tg(myd88:eGFP) transgenic line [26]. These cells
have also been isolated after fixation by flow cytometry of
fast red stained in situ hybridization for cpa5 [27]. The
distinction of zebrafish mast cells from zebrafish eosinophils
has also been addressed using a BAC-engineered transgenic
line expressing GFP from the gata2 promoter. This study
confirmed the presence of and described in detail the char-
acteristics of zebrafish eosinophils. In the Tg(gata2:eGFP)
line, eosinophils express high levels of eGFP and have high
forward and side scatter characteristics by flow cytometry.
These cells were also demonstrated to be functionally orthol-
ogous to human eosinophils [28]. A summary of transgenic
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Figure 1: Overview of zebrafish developmental myelopoiesis, key transgenic lines, and lineage identification tools labelling myeloid cell
populations during developmental haematopoiesis. (Transgenic lines are shown in green, other specific lineage identifiers are in blue.)
PM: primitive myelopoiesis; EMP: erythromyeloid progenitors; HSPCs: haematopoietic stem and progenitor cells; CMP: common myeloid
progenitor; CLP: common lymphoid progenitor; MEP:megakaryocyte/erythroid progenitor; GMP: granulocyte/monocyte progenitor; PHA:
peanut haemaglutinin. ∗∗Denotes lineages only demonstrated in adult zebrafish. Lineage intermediates are shown for clarity but are yet to
be isolated as distinct populations in zebrafish.
lines and markers facilitating myeloid populations is shown
in Figure 1.
As well as facilitating assessment of the ontogeny and
spectrum of zebrafish haematopoietic and immune systems,
the utility of this array of transgenic animals extends to a
more functional analysis of zebrafish haematopoiesis, which
will be particularly useful in zebrafish disease models. Once
again utilizing cell sorting by flow cytometry, Stachura et
al. have established an assay system in which to assess
the clonogenic myeloerythroid capability of subpopulations
of haematopoietic cells [29]. This recent study utilized
traditional clonogenic techniques, commonly used for mam-
malian haematopoietic cell analysis in methylcellulose, facil-
itated by recombinant zebrafish growth factors, erythropoi-
etin and granulocyte colony stimulating factor and serum
derived from carp. Such studies are in their infancy in the
zebrafish system but should lead the way to further capability
to assess clonogenic and lineage potential of individual cells
and populations. Critically, this will allow more detailed
biological analysis of haematopoietic populations which are
currently lacking.
4. Studies of Developmental Myelopoiesis
Many aspects of myelopoiesis have been interrogated using
the zebrafish embryo. Foremost, forward genetic screens
have been employed to identify novel genes required for
primitive or definitive myelopoiesis. The critical role of tran-
scription factors and developmental microenvironment in
determining haematopoietic lineage fate choice has also been
elegantly addressed using this model, using reverse genetics
and transplantation techniques. More recently transient
heterologous overexpression of mutated human oncogenes
has provided some mechanistic insight into the potential
pathogenetic eﬀects of such genes on normal developmental
haematopoiesis and malignant transformation. In addition
functional studies have also addressed aspects of the innate
immune system using the zebrafish (also reviewed elsewhere
in this issue of AIH). What follows is a summary of a
selection of studies in zebrafish that highlight its diverse and
unique capacity to answer a range of biological questions
pertaining to myelopoiesis.
4.1. A Myeloid Mutant Identified in a Forward Genetic
Screen. Several zebrafish studies have identified novel genes
involved in myelopoiesis. Bolli et al. identified the grechetto
mutant with a mutation within the cpsf1 gene from an
early pressure genetic screen for genes involved in definitive
myelopoiesis at 5 dpf. On further investigation, grechetto
mutants displayed pan-haematopoietic defects, arising from
apoptotic cell death of developing haematopoietic stem
and progenitor cells (HSPCs). The CPSF1 protein is part
of a complex of genes required for processing of the 3′UTR
and addition of the poly(A) tail on a subset of pre-mRNAs.
CPSF1 specifically recognizes a canonical polyadenylation
signal within these pre-mRNAs. Bolli et al., showed that
in grechetto mutants the transcript encoding the snRNP70
lacked a poly(A) tail [13]. This gene was also identified
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from a screen for abnormal HSC production [30] and is
of particular note because of its role in normal pre-mRNA
splicing. Since publication of this report in zebrafish, both
loss of function and gain of function mutations in several
genes required for normal splicing have been identified as
contributing to the pathogenesis of human myelodysplastic
syndromes (MDS) [31, 32].
4.2. Lineage Fate Choice Studies. Studies in zebrafish
embryos have also shed light on the lineage fate decisions
during developmental haematopoiesis. Elegant studies of
Rhodes and Galloway showed the interplay between the
major myeloid and erythroid transcription factors pu.1 and
gata-1, respectively, in regulating the fate choice between
erythropoiesis and myelopoiesis [33, 34]. Building on these
studies Monteiro et al. examined the “bloodless” moonshine
mutant carrying a truncating mutation in the transcription
intermediate factor-1γ (ti f 1γ) gene. While previous studies
had demonstrated a requirement for ti f 1γ in maintenance
of primitive erythropoiesis [35], definitive haematopoiesis
had not been examined. In this study Monteiro et al.
showed that HSPCs are specified and emerge normally
from the aorta in moonshine mutants. Subsequently ti f 1γ is
required for normal erythroid diﬀerentiation in the CHT
at 4 dpf, while expression of diﬀerentiated myeloid markers
(mpx and l-plastin) were expanded in the same region.
Moonshine mutants also showed increased levels of pu.1
and reduced levels of gata-1 at this time in the CHT
suggesting that ti f 1γ may interplay with these transcription
factors in the regulation of myeloid versus erythroid fate in
progenitor cells derived from definitive HSCs. To determine
whether these findings may also be relevant to other stages
of haematopoietic development, expression of erythroid
and myeloid lineage markers were assessed in moonshine
mutants along with gata-1 and pu.1 morphants at various
time points during developmental haematopoiesis [36].
The authors concluded that ti f 1γ modulates the erythro-
myeloid fate choice by regulating the expression of gata-1
and pu.1, and this regulation showed distinct patterns during
specific phases of developmental haematopoiesis. This study
demonstrated a novel role for ti f 1γ as a regulator of cell
fate decisions, and also highlighted the dynamic changes
in levels of transcription factors and their interactions that
occur during developmental haematopoiesis.
A recent study by Li et al., has also addresses lineage fate
decisions between the macrophage versus the granulocytic
lineages. In this study the interferon regulatory factor 8
(irf8) was identified as a novel regulator of terminal myeloid
diﬀerentiation downstream of pu.1, that promoted the
development of the macrophage lineage at the expense of
neutrophils during primitive and definitive haematopoiesis
[37]. Morpholino knockdown of irf8 depleted the number
of embryonic macrophages and expanded the neutrophil
population with the underlying mechanism determined to
be a cellular fate switch. There was no definitive evidence
for decreased neutrophil apoptosis or increased proliferation
to account for increased neutrophil numbers and double-
labelling of l-plastin and mpx or fms in irf8 morphants
revealed a predominance of l-plastin and mpx positive
cells. Transgenic overexpression of irf8 achieved through
generation of a Tg(hsp70:irf8myc ) transgenic line, promoted
macrophage development at the expense of neutrophils [37],
but could not rescue macrophage development following
pu.1-morpholino injection. Interestingly, Irf8-mutant mice
develop a chronic-myelogenous-leukaemia- (CML-) like
syndrome with elevated numbers of neutrophils [38, 39].
Taken in this context, this study not only identifies a novel
role for irf8 in normal myelopoiesis, but also highlights
mechanisms that could be possibly hijacked during leukae-
mogenesis.
4.3. Functional Assessment of Human Leukaemia Mutations
Using Developmental Myelopoiesis. Novel insights into the
biology of haematopoietic malignancies have also been
gained using zebrafish models expressing haematopoietic
oncogenes as detailed in the subsequent section. However,
one recent study has harnessed the developmental myeloid
phenotype of a zebrafish mutant to functionally interrogate
the eﬀects of human nonsynonymous sequence variants
(NSVs) found in human acute myeloid leukaemia (AML).
In this study ddx18 mutant zebrafish were shown to have
aberrant myelopoiesis resulting from p53-dependent cell
cycle arrest. Sanger sequencing of the DDX18 gene then
identified 4 NSVs in samples from patients with AML.
Rescue experiments were then performed using the ddx18
mutant zebrafish and identified that one of the NSVs
appeared to exert a dominant negative eﬀect on developmen-
tal myelopoiesis [40]. While this study was based on Sanger
sequencing targeting the DDX18 gene, it paves the way to
utilize the zebrafish for other such strategies to interrogate
novel NSVs now being identified in the thousands from
whole genome andwhole exome sequencing eﬀorts, for func-
tional relevance. Furthermore the value of this strategy will
become even more powerful as additional models of existing
known leukaemic variants and oncogenes become more
prevalent, facilitating combined knockdown/overexpression
studies using the existing models to test NSVs.
4.4. Heterologous Overexpression Studies. Overexpression
and knockdown studies of myeloid oncogenes and tumour
suppressor genes, respectively, have also been informative in
studies using the zebrafish embryo. The nucleophosmin 1
(NPM1) gene encoding the ubiquitous nucleolar phospho-
protein nucleophosmin is lost in over one-third of patients
with AML or MDS associated with loss of chromosome 5q
[41]. In addition heterozygous gain-of-function mutations
in NPM1 are the most common mutations found in AML
accounting for one-third of cases with normal karyotype
[42]. Structurally, these mutations result in the generation
of a novel nuclear export signal and loss of nucleolar local-
ization signal and thus, in contrast to the normal exclusively
nucleolar localization of NPM, mutated NPM is located in
the nucleolus, nucleoplasm, and cytoplasm [43]. Further-
more, because NPM contains an oligomerisation domain,
NPMmutants relocate at least some of the residual wild-type
NPM to the cytoplasm and nucleoplasm. SuchNPMmutants
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have therefore been named NPMc+ to denote their cyto-
plasmic localization. Heterologous overexpression of the
most common NPM1 mutation resulting in NPMc+ (NPM
mutant A) was undertaken in a study by Bolli et al. Over-
expression of NPMc+ resulted in mislocalization of the
zebrafish orthologues of NPM1 (npm1a and npm1b) to the
cytoplasm indicating that human NPM can oligomerize with
the zebrafish Npm genes. In addition, primitive myeloid cell
numbers were increased, as were c-myb expressing cells in the
ventral wall of the aorta and gata1/lmo2 double expressing
cells in the CHT. This data suggested that NPMc+ mutant
protein led to the expansion of HSPCs as well as developing
primitive myeloid and erytho-myeloid progenitor cells [44].
Interestingly, such expansion of myeloid progenitors has also
subsequently been demonstrated in a mouse knockin model
of NPMc+ mediated leukaemia [45].
4.5. Innate Immune System. Cells of the myeloid lineage
form the principle components of the innate immune system
and, as such, production and development of such cells
are stimulated upon exposure to pathogens. G-CSF/CSF3
and its receptor, CSF3R, have well-established roles in
haematopoiesis, directing myeloid diﬀerentiation of HSCs
and proliferation of progenitors [46]. In particular, CSF3
is strongly expressed in response to microbiological toxins
in the blood, such as bacterial lipopolysaccharide (LPS), to
promote myelopoiesis (especially granulocytes) and cellular
migration towards the infection site [47]. Zebrafish possess a
homologous csf3/csf3r signalling axis that functions similarly
to its mammalian counterpart [48]. Overexpression of
csf3 mRNA expands embryonic myelopoiesis, but loss of
zebrafish csf3r blocks myelopoiesis entirely with losses of
fms-, lyz-, and mpx-expressing populations. Furthermore,
exposing embryos to LPS stimulates csf3 and csf3r expression,
and leads to an “emergency” increase in lyz-expressing
granulocytes in a csf3r-dependent manner.
Inducible nitric oxide (iNOS/NOS2) signalling also
participates in the inflammatory response to infection.
The zebrafish homologue, nos2a, appears to be dispensable
for normal formation of HSPCs [49]. However, using
morpholinos and L-NAME or L-NMMA (pan-NOS phar-
macologic inhibitors), Hall et al. determined that Nos2a
protein is required downstream of C/ebpβ to expand the
HSPC population (as evidenced by increased c-myb and
runx1 expression) and promote myeloid diﬀerentiation in
response to Salmonella infection [50]. In this study, zebrafish
nos2a appears to primarily favour production of neutrophil
granulocytes (evidenced by increased lyz expression). Hall
et al. further confirmed the importance of csf3r signalling
for “emergency” myelopoiesis during infection, as csf3r mor-
phants could not mount a myeloid response upon exposure
to Salmonella.
5. Lessons from Transgenic Zebrafish Models of
Myeloid Malignancies
Aged wild-type zebrafish (24+months) are susceptible to the
development of a spectrum of neoplasms with an incidence
rate around 11% [3], however the incidence of haematopoi-
etic malignancies is rare. Studies of transgenic zebrafish,
with tissue specific or ubiquitous promoters driving human
or murine oncogenes, have however resulted in faithful
models of myeloid leukaemias with features of their human
disease counterparts. Below is a summary of the existing
models of myeloid leukaemia, the novel findings such
models have contributed to our understanding of human
myeloidmalignancies and a critique of existing and emerging
technologies within this field.
5.1. K-RAS. Le et al. developed a model of K-RAS-medi-
ated malignant disease by generating a Cre/lox-inducible
K-RASG12D allele driven by the β-actin promoter. Tg(β-
actin:loxP-eGFP-loxP:K-RASG12D) zebrafish crossed to a
zebrafish carrying a heat shock promoter (hsp70) driving
cre expression resulted in the development of a myelopro-
liferative neoplasm (MPN) between 34 to 66 days of life,
with increased myelomonocytes and myeloid precursors in
kidney marrow, and a significant loss of mature erythrocytes
[51]. Notably these malignancies occurred in the absence
of any heat shock and were rare in animals that had been
exposed to heat shock. Sibling animals exposed to heat shock
developed more aggressive, nonhaematopoietic neoplasms
such as rhabdomyosarcoma and died as a result of these
in early life, suggesting that only low doses of activated
K-RAS were necessary to transform haematopoietic cells,
or that expression of cre from the hsp70 promoter in the
haematopoietic lineage was greater or more leaky than in
other tissues.
5.2. MOZ-TIF2. Using the pu.1 promoter to drive transgene
expression in myeloid cells, Tg(pu.1:MOZ-TIF2-eGFP) fish
were the first to demonstrate overt AML in zebrafish at 14
to 26 months of life, showing an accumulation of immature
myelomonocytes in the kidney marrow and a reduction in
haematopoietic cells within the spleen [52]. It is notable,
however, that both Tg(β-actin:K-RAS) and Tg(pu.1:MOZ-
TIF2-EGFP) fish showed a low penetrance of disease, and
their underlying molecular mechanisms remain unexplored.
5.3. Tel-jak2a. A handful of studies have provided more
mechanistic insight into oncogenic activity in zebrafish
myelopoiesis. In such a study, Tg(pu.1:FLAG-tel-jak2a) fish
utilized a fusion oncogene created from the zebrafish ortho-
logues of TEL and JAK2, rather than use of human cDNA
[53]. In embryos, tel-jak2a expression leads to an accumula-
tion of large myeloid cells in blood smears, induction of the
cell cycle, and a gain in cells expressing the myeloid markers
pu.1 and l-plastin at 24 hpf. Interestingly, despite a loss of
circulating mature erythrocytes by 48 hpf, Tg(pu.1:FLAG-tel-
jak2a) fish also showed expanded distribution of erythroid
markers gata1 and βe3-globin at 24 hpf and 48 hpf. This is
in keeping with other studies of Janus kinase/signal trans-
ducer and activator of transcription (JAK/STAT) signalling
having wide-ranging eﬀects on haematopoiesis in zebrafish
embryos. For example, mutant chordin zebrafish that over-
express jak2a also show upregulation of both erythroid
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and myeloid genetic markers [54]. This phenotype in
chordin mutants could be rescued by injection of jak2a
morpholino or pharmacological treatment with the Jak2
inhibitor, AG490, and phenocopied in wild-type embryos
by injection of constitutively active jak2a mRNA. This
study also suggested that the likely mechanism for the
haematopoietic phenotype was hyperphosphorylation of
Stat5 because the injection of zebrafish stat5 mRNA carrying
a hyperactive H298R/N714F mutation led to increases in
erythroid, myeloid, and B cell numbers [55]. Similar findings
were observed in a zebrafish model of the myeloprolifer-
ative disease, polycythemia vera (PCV), where erythroid
dysregulation by jak2aV581F mRNA could be rescued by
injection of stat5 morpholino [56]. Despite these promising
embryonic findings, however, none of the Tg(pu.1:FLAG-tel-
jak2a) transgenic embryos survived to adulthood [53].
5.4. NUP98-HOXA9. Recently, our group described
a myeloid-specific, Cre/lox-inducible Tg(pu.1:NUP98-
HOXA9) fish line that exhibits MPN in 23% of fish between
19 and 23 months of life [57]. Despite evidence of myeloid
proliferation and delayed cell maturation in kidney marrow,
no animals were identified with overt AML. However,
mechanistic insights were gained at the embryonic level.
Following DNA-damaging irradiation, Tg(pu.1:NUP98-
HOXA9) embryos showed increased numbers of cells in
G2-M transition compared to controls and absence of
a normal apoptotic response, which may result from an
upregulation of bcl2. Furthermore, embryos showed altered
haematopoiesis at 28 hpf, with increased myeloid develop-
ment marked by pu.1, l-plastin, and lysc, at the expense of
erythroid development marked by gata1, suggesting that
expression of the NUP98-HOXA9 fusion oncoprotein
is capable of altering the cell fate and myeloid cell
diﬀerentiation. These early phenotypes in Tg(pu.1:NUP98-
HOXA9) embryos highlight a potential mechanism whereby
HSPCs carrying this oncogene have increased likelihood of
acquiring additional mutations due to their impaired DNA
damage response and also carry an aberrant population of
less diﬀerentiated myeloid cells that may be preferentially
targeted and thus may mechanistically account for the
predisposition of these fish to develop overt MPNs [57].
5.5. AML1-ETO. Expression of the AML1-ETO oncogene,
driven by the heat shock protein 70 (hsp70) promoter
also results in disruption of developmental myelopoiesis
in zebrafish embryos [58]. In this study, embryos show
the appearance of cells with blast-like morphology, as well
as upregulation of pu.1 and downregulation of gata1 at
20–22 hpf. Interestingly, there was a diﬀerential impact on
more mature myeloid lineages, with increased granulocytes
marked by mpx, but decreased numbers of cells expressing
l-plastin. The transforming mechanism was identified as a
downregulation of scl, one of the master transcription factors
for embryonic haematopoiesis. All phenotypes were rescued
by injecting Tg(hsp70:AML1-ETO) embryos with either scl
mRNA or pu.1 morpholino.
To date, the Tg(hsp70:AML1-ETO) line represents the
most successful use of zebrafish to study the molecular biol-
ogy of myeloid leukaemia. Despite the absence of an overt
adult disease phenotype, Tg(hsp70:AML1-ETO) embryos
have been an instrumental research tool in the identification
of genetic and chemical modifiers of myeloid oncogenesis.
A subset of human AML cases show deletions on chromo-
some 9q, which are specifically associated with the t(8;21)
translocation yielding AML1-ETO. The eﬀects of del(9q)
result from the loss of two genes, transducin-like enhancer
of split 1 (TLE1) and TLE4, in the Notch signaling pathway.
A reverse genetics approach used morpholino knockdown
of the zebrafish TLE homolog, groucho3, in Tg(hsp70:AML1-
ETO) embryos to show an acceleration of the haematopoietic
phenotype, namely the appearance of blast-like cells, the
increase in mpx expression, and a loss of circulating ery-
throcytes [59]. In human AML, the AML1-ETO oncoprotein
disrupts epigenetic programming through recruitment of
histone deacetylase complexes (HDAC), which can be
pharmacologically targeted by HDAC inhibitors such as
trichostatin A (TSA). Taking advantage of this phenotype,
Yeh and colleagues used the rescue of gata1 expression by
TSA as a proof of principle springboard for a chemical
modifier screen with a library of known bioactive com-
pounds [60]. Interestingly, they identified COX2 inhibitors,
such as NS-398 and indomethacin, as novel therapeutic
agents against AML1-ETO, and subsequently demonstrated
the critical importance of COX2-prostaglandin E2 signalling
through the Wnt/β-catenin pathway [61] to the altered
haematopoiesis in Tg(hsp70:AML1-ETO) fish. This proved
to be an important discovery—soon after, this same pathway
and therapeutic strategy was identified in a mouse model of
Hoxa9;Meis1-induced AML [62].
5.6. Technical Challenges and Advances. The reason behind
the long latency and low penetrance of overt myeloid
leukaemia in zebrafish models of this disease may lie in
part with the lack of available myeloid-targeted promoters
that are active in early blood cells. Even with the success
of the pu.1 promoter used in several studies, endogenous
zebrafish pu.1 expression is downregulated during terminal
myeloid diﬀerentiation, and has been found to be active
in only ∼2% of adult haematopoietic kidney marrow cells
[16]. This could account for the low incidence of AML in
Tg(pu.1:MOZ-TIF2-eGFP) fish and the lack of progression
to overt AML in Tg(pu.1:NUP98-HOXA9) fish. Targeted
promoters have also proven troublesome in other models
of fish leukaemia. Sabaawy et al. showed that expression of
the oncogene TEL:AML1 from ubiquitous zebrafish β-actin
and xenopus elongation factor 1 (Xef1) promoters but not
early lymphoid targeted fish using the rag2 promoter could
produce pre-B (ALL) [63]. Such lessons suggest that the
use of promoters that are active earlier in zebrafish blood
development may prove more robust at driving leukaemic
transformation. However, the use of ubiquitous promoters
carry the caveat of oﬀ-target eﬀects, as seen in Tg(β-actin:K-
RASG12D) fish where MPN was one of a spectrum of
disease phenotypes, including rhabdomyosarcoma, intestinal
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hyperplasia, and malignant peripheral nerve sheath tumours
[51].
Potency of the oncogenic signal is another hurdle to
successfully modelling leukaemia in fish. For example,
Tg(pu.1:FLAG-tel-jak2a) fish as well as the early models
of Tg(rag2:eGFP-Myc) fish [2] display such severe abnor-
malities that animals do not survive to breeding age, and
so embryos must be reinjected for every study. Cre/lox-
inducible strategies can be helpful to establish germline
transmission of the oncogene, but historically the most
reliable method to control Cre activity was to use the hsp70
promoter, which is known to have leaky expression [51, 57].
This in turn has also suggested that oncogene dosage is likely
to have a direct impact on the penetrance and type of malig-
nancies induced as described above for the Tg(β-actin:loxP-
eGFP-loxP:K-RASG12D) [51]. Direct use of the hsp70 pro-
moter to drive oncogene expression has proven fruitful in the
study of AML1-ETO, but the absence of an adult phenotype
may reflect the transience of promoter activity following
heat-shock activation. Tamoxifen-inducible Cre recombinase
(Cre-ERT2) may allow tighter temporal control of transgene
expression [64] and can dramatically improve the leaky
expression in Tg(hsp70:Cre) animals [65]. Hans et al. show
that, even at temperature ranges of 37–42◦C, recombination
events can be blocked completely in Tg(hsp70:Cre-ERT2)
animals if tamoxifen is not applied following heat shock.
Other intriguing developments include the generation of
zebrafish with mosaic expression of oncogenic transgenes
[66, 67] allowing more detailed analysis of the eﬀect on
oncoprotein expression in individual cells. In mice, the use of
lineage-restricted myeloid promoters, for example, Catheps-
inG [68, 69], Mrp8 [69, 70], has not limited the success of
oncogenic transformation and, in fact, committed myeloid
progenitor cells have been identified as the leukaemia-
initiating cell (LIC) in many karyotypes of AML [69–73].
In the zebrafish, the use of more lineage-restricted myeloid
promoters (i.e., lysc, mpx, mpeg, fms) have flourished in the
field of leukocyte traﬃcking [17, 22, 23, 74] so these may
ultimately provide alternative tools for future fish models of
myeloid leukaemogenesis.
Finally, given that overt AML has been achieved in only
one zebrafish model to date suggests that the acquisition
of mutations within collaborating proto-oncogenes and/or
inactivation of tumour suppressor genes may occur less read-
ily in the short life expectancy of the zebrafish. Alternatively,
the acquisition of disease promoting cooperating mutations
may be masked by increased genetic redundancy that has
resulted from the additional round of gene duplication
undergone in the teleost genome. However, the zebrafish is
well suited to test specific interactions between collaborating
oncogenes due to its high fecundity and thus capacity to
generate large number of animals with a range of genotypes,
as recently demonstrated in neuroblastoma by Zhu et al.
[75]. Transgenic fish harbouring multiple oncogenes have
also been a successful strategy for modulating the incidence
of zebrafish ALL [76]. Thus future strategies to assess the
contribution of collaborating mutations could be targeted at
overexpression/knockdown strategies of two, three, or four
genes.
Until recently, stable gene knockout studies of tumour
suppressor genes have been diﬃcult to achieve in most
zebrafish laboratories. While the clinical relevance of such
models is apparent from mutant alleles derived from
targeting induced local lesions in Genomes (TILLING),
such as p53 mutant animals [77–79], targeted, heritable
gene knockdown in zebrafish has been a major challenge
for the community over the past decade. The last few
years have seen a major sea change with the snowballing
of technical advances in this regard. Initial reports of
zinc finger nuclease- (ZFN-) induced cleavage and repair
resulting in gene knockouts from two groups [80, 81]
followed shortly by the publication of the oligomerized pool
engineering (OPEN) system for in vitro identification and
validation of potential gene targeting zinc fingers by Keith
Joung’s laboratory [82, 83] have highlighted the potential
to harness this technology even in smaller laboratories. Less
than 2 years later, the same groups had further refined
their in vitro and in silico systems to allow accuracy in
identification of target sites using bioinformatics alone
[84]. Most recently, evidence has shown that transcriptional
activator-like nucleases (TALENs), engineered from DNA
binding proteins of the Xanthomonas bacteria function
even more faithfully in the zebrafish system to target the
enzymatic cleavage component of the FOK1 endonuclease
to within a few bases of the desired double stranded
DNA break [85, 86]. Of course we continue to avidly
anticipate the optimization of homologous recombination
methodologies to finally permit conditional knockin models
of disease.
6. Using the Zebrafish as a Xenograft Model
for Myeloid Leukaemia
Overall, compared to the lymphoid tumours, models
of myeloid leukaemia are relatively less penetrant with
leukaemia rates ranging from 25% [51] to <1% [52]. The
generation of novel promoters may facilitate more faithful
models of human myeloid disease in zebrafish. In particular,
dissection of the zebrafish runx1 promoters has provided
new insights into the regulation of this gene in zebrafish
but may also prove to be a better driver of oncogene-
induced malignant myeloid disease [87]. One potential
complimentary strategy is the recent interest in developing
methodologies for xenotransplantation of human or mouse
cancer cells into zebrafish and applying this approach to
myeloid disease [88]. Tissue culture assays and animal mod-
els have been instrumental in determining key molecular
pathway in cancer and novel drug development. However, in
vitro assays lack the critical context of the tumour microen-
vironment, while mouse xenografts are cost-prohibitive and
require extensive engraftment time. By contrast, the use
of zebrafish facilitates scalability, where large numbers of
rapidly developing, externally fertilized transparent embryos
can be used to screen compounds in a high-throughput
manner. By using embryos at 48 hpf, xenograft rejection is
minimized, by virtue of their lack of an adaptive immune
system during the first week of life [89].
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Figure 2: Schematic of in vivo cell proliferation assay in xenotransplanted zebrafish embryos. Human leukemia cells are fluorescently labelled
with a cell tracking dye. Approximately 25–50 fluorescently labelled cells are microinjected into the yolk sac of 48 hpf casper embryos.
Embryos are screened using fluorescent microscopy for the presence of a fluorescent mass at the site of injection. Positive embryos are
divided into two groups; one of which is maintained at 35C for 24 h, and the other group is maintained for until the time point of interest
with or without drug exposure. At the end of each time point embryos are enzymatically dissociated to a single cell suspension and the
number of fluorescent cells in the suspension is counted using a semiautomated macro in Image J (NIH, Bethesda, MD). The number of
fluorescent cells present at the later time point divided by the number of fluorescent cells present at 24 h represents the fold increase in cell
number. Adapted from Corkery et al. [90].
A number of anatomic sites in the embryo have been
trialled for xenografting, but the yolk sac is generally
considered the ideal anatomic location and has been used in
the leukaemia xenotransplantation studies to date [90, 91].
Incubation of xenografted embryos at 35◦C enables growth
of injected human cell lines in a fully constituted, 3D, in
vivo microenvironment, without compromising zebrafish
embryogenesis [89, 90, 92]. Two groups, including ours,
have exploited xenotransplantation for the study of myeloid
leukaemias [90, 93]. Both groups demonstrated success-
ful engraftment and proliferation of CM-DiI fluorescently
labelled K562 erythroleukemia and NB4 acute promyelocytic
leukaemia (APL) cell lines following yolk sac injection in
48 hpf zebrafish embryos. Moreover, response to targeted
therapy with imatinib mesylate in K562 cells harbouring
the BCR-ABL1 oncoprotein or with all-trans retinoic acid
(ATRA), a targeted inhibitor of the PML-RARα oncoprotein
found in NB4 cells was observed with the addition of these
compounds to the water of xenografted embryos. Pruvot
et al. observed a reduction in the number of xenografted
K562 cells upon exposure to imatinib and a dose-dependent
teratogenic eﬀect and death of NB4 cell xenografted embryos
treated with ATRA. Our group have developed a robust ex
vivo cell proliferation assay to quantify cell numbers over
time following xenotransplantation (Figure 2) and demon-
strated that xenografted K562 cells specifically responded to
imatinib, resulting in decreased cell numbers but no embry-
onic toxicity. Similar results were obtained with ATRA for
xenografted NB4 cells. Importantly, when therapeutic agents
were swapped and applied against the opposite cell type,
leukaemia cells continued to proliferate demonstrating that
human cancer cells can be specifically targeted in a zebrafish
xenotransplantation model. These studies open the door for
using the zebrafish xenotransplantation platform to rapidly
assess the eﬃcacy of novel compounds on the proliferation
of human leukaemia cells in vivo. Xenotransplantation could
also enable screens of currently available anticancer agents
for oﬀ-label, in vivo activity against human leukaemia cells.
More recently, as has been demonstrated for some gastroin-
testinal tumours [94], we have undertaken studies using pri-
mary leukaemia patient-derived bone marrow (Tugce Balci,
Dale Corkery, Graham Dellaire and Jason Berman, unpub-
lished results). We have seen similar robust engraftment,
proliferation, and circulation of primary leukaemia samples
and confirmed this process to be an active process, requiring
functional living cells, as fixed control cells remained in
the yolk. Other groups have further demonstrated diﬀeren-
tial engraftment of human leukemia subpopulations, with
engraftment of CD34+ putative leukaemia stem cells but
not from CD34− cells, indicating that zebrafish models may
reflect the biology of disease in a similar way as mouse
models and enable studies on tumorigenicity and tumour
stem cells [93, 95, 96]. In parallel, with other tools, such as
the development of syngeneic fish lines (CG1) [76] and the
casper mutant fish line that permanently maintains trans-
parency into adulthood [97], xenotransplantation will enable
the zebrafish to explore questions of leukemia initiating cell
frequency, clonogenicity, and the ability to serially transplant
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disease. Given the complexity of genetic lesions that can
present in AML and the heterogeneity of treatment response
inherent in this disease, xenotransplantation models could
ultimately be used in real-time analysis of primary patient
biopsies as an informative diagnostic tool to predict eﬀective
therapeutic regimens and/or inform subsequent preclinical
murine studies of promising novel agents, ultimately leading
to Phase I clinical trials.
7. Conclusions and Future Studies
The zebrafish embryo has contributed significantly to our
understanding of the developmental biology of haemat-
opoiesis and myelopoiesis over the past decade. The expon-
ential rise in our ability to dissect the biology of myeloid cells
in this small vertebrate will no doubt fuel further insights
and broaden the scope for current models of myeloid
leukaemias. The advent of TALENs and zinc finger nucleases
as well as the zebrafish mutation project at the Sanger Centre
(http://www.sanger.ac.uk/Projects/D rerio/zmp/) promises
to deliver us knockouts for all genes in the zebrafish genome
that will greatly enhance future studies, particularly of
tumour suppressor genes in myeloid disease.
The forward genetic screens that identified so many
novel mediators of haematopoiesis in the late 90’s [98, 99]
including identification of a novel human disease gene [100]
have been somewhat out of vogue in recent years. However,
completion of the sequencing of the zebrafish genome
alongside rapidly reducing costs and improving technology
for deep sequencing methodologies are likely to enhance our
ability to map such mutations, even in more complex genetic
backgrounds. Thus genetic modifier screens of phenotypes
observed inmyeloidmalignancies or developmentmay prove
fruitful in the future.
One of the greatest promises for the future of the
zebrafish model is its ability to make a significant contribu-
tion to the field of myeloid leukaemogenesis by identifying
novel therapeutic compounds through chemical screens tar-
geting developmental or early larval phenotypes. The ability
to undertake larger scale screening projects even within the
environment of academia is becoming more accessible across
the zebrafish community and is being enhanced by the
application of this platform to xenogeneic cells as well as
recent advances in automated image acquisition and analysis
capabilities [101]. The growing recognition and acceptance
of the zebrafish for studying myeloid biology will enable
it to secure a place among other model systems including
mouse and cell culture, as a component in a pipeline of
preclinical tools to better interrogate molecular pathways
and rapidly identify novel therapies with conserved eﬀects
across organisms likely to impact outcome for patients with
myeloid diseases.
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